Literature DB >> 17332627

Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro.

Charlotta Lundh1, Madeleine M Nordén, Mikael Nilsson, Eva Forssell-Aronsson.   

Abstract

UNLABELLED: Thyroid stunning refers to reduced uptake of (131)I in the thyroid tissue (or tumor) during radioiodine ((131)I) therapy compared with the uptake measured after the previous administration of (131)I for diagnostic purposes. The phenomenon is clinically important, as it can potentially lead to the undertreatment of thyroid cancer or to unnecessarily high absorbed doses in critical organs. Previous clinical and experimental studies indicated that thyroid stunning is absorbed dose dependent. The aim of this study was to investigate the effects of (131)I irradiation on (125)I(-) transport and cell proliferation at low absorbed doses in vitro.
METHODS: Primary cultured porcine thyroid cells were grown to form a confluent monolayer of epithelial cells on a filter in a bicameral culture system. The cells were continuously irradiated with (131)I in the culture medium for 48 h to obtain 0.0015-1.5 Gy. At 3 d after irradiation was stopped, the transepithelial iodide transport capacity was evaluated by measuring (125)I(-) transport from the basal chamber compartment to the apical chamber compartment. The effect of (131)I irradiation on DNA synthesis was estimated by pulse labeling with (3)H-thymidine of both subconfluent and confluent cells irradiated with up to 9 Gy. Total DNA content was measured to quantify cell numbers.
RESULTS: A statistically significant reduction in (125)I(-) transport was seen at absorbed doses of >or=0.15 Gy, with a 50% reduction at 1.5 Gy, compared with the results observed for nonirradiated control cells. (3)H-Thymidine incorporation was already statistically significantly reduced at absorbed doses of 0.01-0.1 Gy, but 0.15-0.3 Gy did not affect DNA synthesis. However, absorbed doses of >or=1 Gy again resulted in reduced DNA synthesis. A 50% reduction was obtained at 4 Gy. Total DNA measurements revealed a statistically significant reduction in cell numbers at 8 Gy.
CONCLUSION: The lowest absorbed dose from (131)I that reduced iodide transport was 0.15 Gy. Because stunning was found at low absorbed doses, it might occur for (131)I treatment not only of thyroid cancer but also of thyrotoxicosis. On the basis of differences in dose responses, radiation-induced thyroid stunning and cell cycle arrest may be independent phenomena.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332627

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Comparing pre-therapeutic 124I and 131I uptake tests with intra-therapeutic 131I uptake in benign thyroid disorders.

Authors:  Falk Gühne; Christian Kühnel; Martin Freesmeyer
Journal:  Endocrine       Date:  2017-03-07       Impact factor: 3.633

2.  Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases.

Authors:  C Happel; W T Kranert; D Gröner; B Bockisch; A Sabet; I Vardarli; R Görges; K Herrmann; F Grünwald
Journal:  Endocrine       Date:  2020-03-16       Impact factor: 3.633

3.  Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.

Authors:  Christian Happel; Wolfgang Tilman Kranert; Hanns Ackermann; Ina Binse; Benjamin Bockisch; Daniel Gröner; Ken Herrmann; Frank Grünwald
Journal:  Endocrine       Date:  2018-12-31       Impact factor: 3.633

4.  The Effect of Diagnostic Absorbed Doses from 131I on Human Thyrocytes in Vitro.

Authors:  Zbigniew Adamczewski; Mariusz Stasiołek; Bolesław Karwowski; Marek Dedecjus; Daria Orszulak-Michalak; Anna Merecz; Przemysław W Śliwka; Bartosz Puła; Andrzej Lewiński
Journal:  Int J Mol Sci       Date:  2015-06-29       Impact factor: 5.923

5.  Non-parametric intravoxel incoherent motion analysis of the thyroid gland.

Authors:  Anton S Becker; Moritz C Wurnig; Tim Finkenstaedt; Andreas Boss
Journal:  Heliyon       Date:  2017-01-30

6.  The Molecular Effect of Diagnostic Absorbed Doses from 131I on Papillary Thyroid Cancer Cells In Vitro.

Authors:  Mariusz Stasiołek; Zbigniew Adamczewski; Przemysław W Śliwka; Bartosz Puła; Bolesław Karwowski; Anna Merecz-Sadowska; Marek Dedecjus; Andrzej Lewiński
Journal:  Molecules       Date:  2017-06-15       Impact factor: 4.411

7.  Statistical and radiobiological analysis of the so-called thyroid stunning.

Authors:  Stephan Walrand; Michel Hesse; François Jamar
Journal:  EJNMMI Res       Date:  2015-11-19       Impact factor: 3.138

8.  ⁹⁹mTcO₄--, auger-mediated thyroid stunning: dosimetric requirements and associated molecular events.

Authors:  Béatrice Cambien; Philippe R Franken; Audrey Lamit; Thibault Mauxion; Peggy Richard-Fiardo; Julien Guglielmi; Lydie Crescence; Bernard Mari; Thierry Pourcher; Jacques Darcourt; Manuel Bardiès; Georges Vassaux
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

9.  The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation.

Authors:  Muthiah Subramanian; Manu Kurian Baby; Krishna G Seshadri
Journal:  Endocr Connect       Date:  2016-01-15       Impact factor: 3.335

10.  A Clinical Trial of Optimal Time Interval Between Ablation and Diagnostic Activity When a Pretherapy RAI Scanning Is Performed on Patients With Differentiated Thyroid Carcinoma.

Authors:  Yafu Yin; Qiufen Mao; Song Chen; Na Li; Xuena Li; Yaming Li
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.